according to the Hazardous Products Regulations



# **Cefuroxime Formulation**

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 2.3 11/30/2023 10844573-00005 Date of first issue: 09/06/2022

#### **SECTION 1. IDENTIFICATION**

Product name : Cefuroxime Formulation

Other means of identification : Spectrazol Milking Cow (A005270)

Coopers Cepravin LC Lactating Cow Intramammary Antibiotic

(47941)

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product Restrictions on use : Not applicable

#### **SECTION 2. HAZARDS IDENTIFICATION**

GHS classification in accordance with the Hazardous Products Regulations

Respiratory sensitization : Category 1

Specific target organ toxicity

- repeated exposure

Category 2

**GHS** label elements

Hazard pictograms



Signal Word : Danger

Hazard Statements : H334 May cause allergy or asthma symptoms or breathing diffi-

culties if inhaled.

H373 May cause damage to organs through prolonged or re-

peated exposure.

Precautionary Statements : Prevention:

P260 Do not breathe mist or vapors. P284 Wear respiratory protection.

Response:

P304 + P340 IF INHALED: Remove person to fresh air and

keep comfortable for breathing.

P342 + P311 If experiencing respiratory symptoms: Call a doc-

tor.

Disposal:

according to the Hazardous Products Regulations



# **Cefuroxime Formulation**

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 2.3 11/30/2023 10844573-00005 Date of first issue: 09/06/2022

P501 Dispose of contents and container to an approved waste

disposal plant.

Other hazards

None known.

#### **SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

Components

	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Cefuroxime	No data availa- ble	55268-75-2	8.33

#### **SECTION 4. FIRST AID MEASURES**

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

If not breathing, give artificial respiration. If breathing is difficult, give oxygen.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Get medical attention if symptoms occur. Flush eyes with water as a precaution.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

Most important symptoms

and effects, both acute and

delayed

May cause allergy or asthma symptoms or breathing difficul-

ties if inhaled.

May cause damage to organs through prolonged or repeated

exposure.

Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reac-

tive airways dysfunction syndrome).

Protection of first-aiders : First Aid responders should pay attention to self-protection.

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

## **SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

according to the Hazardous Products Regulations



# **Cefuroxime Formulation**

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 2.3 11/30/2023 10844573-00005 Date of first issue: 09/06/2022

Unsuitable extinguishing

media

: None known.

Specific hazards during fire

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides

Nitrogen oxides (NOx)

Sulfur oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment:

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

## **SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protec: :

tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g., by containment or

oil barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Soak up with inert absorbent material.

For large spills, provide diking or other appropriate

containment to keep material from spreading. If diked material

can be pumped, store recovered material in appropriate

container.

Clean up remaining materials from spill with suitable

absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

## **SECTION 7. HANDLING AND STORAGE**

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation Advice on safe handling Use only with adequate ventilation. Do not breathe mist or vapors.

Do not swallow.

Avoid contact with eyes.

according to the Hazardous Products Regulations



# Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 11/30/2023 10844573-00005 Date of first issue: 09/06/2022 2.3

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Keep container tightly closed.

Already sensitized individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease,

should consult their physician regarding working with

respiratory irritants or sensitizers.

Take care to prevent spills, waste and minimize release to the

environment.

Keep in properly labeled containers. Conditions for safe storage

Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid Do not store with the following product types:

Strong oxidizing agents

Gases

#### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis	
Cefuroxime	55268-75-2	TWA	100 μg/m3 (OEB 2)	Internal	
	Further information: RSEN				

Use appropriate engineering controls and manufacturing **Engineering measures** 

technologies to control airborne concentrations (e.g., drip-

less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Laboratory operations do not require special containment.

Personal protective equipment

Respiratory protection If adequate local exhaust ventilation is not available or

exposure assessment demonstrates exposures outside the

recommended guidelines, use respiratory protection.

Filter type

Hand protection Material

Chemical-resistant gloves

Eye protection Wear safety glasses with side shields or goggles.

Particulates type

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection

Work uniform or laboratory coat.

Hygiene measures If exposure to chemical is likely during typical use, provide

according to the Hazardous Products Regulations



# **Cefuroxime Formulation**

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 2.3 11/30/2023 10844573-00005 Date of first issue: 09/06/2022

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

#### **SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance : liquid

Color : white

off-white

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

according to the Hazardous Products Regulations



# **Cefuroxime Formulation**

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 2.3 11/30/2023 10844573-00005 Date of first issue: 09/06/2022

Partition coefficient: n-

octanol/water

: Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : Not applicable

## **SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reac- : Can react with strong oxidizing agents.

rossibility of flaz

Conditions to avoid

tions

: None known.: Oxidizing agents

Incompatible materials

Hazardous decomposition

products

No hazardous decomposition products are known.

## **SECTION 11. TOXICOLOGICAL INFORMATION**

## Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

## **Acute toxicity**

Not classified based on available information.

## **Components:**

#### Cefuroxime:

Acute oral toxicity : LD50 (Rat): > 10,000 mg/kg

LD50 (Mouse): > 10,000 mg/kg

Acute toxicity (other routes of :

administration)

LD50 (Rat): > 4,000 mg/kg Application Route: Intravenous

LD50 (Mouse): > 10,000 mg/kg Application Route: Intravenous

according to the Hazardous Products Regulations



# **Cefuroxime Formulation**

Version Re 2.3 11

Revision Date: 11/30/2023

SDS Number: 10844573-00005

Date of last issue: 09/30/2023 Date of first issue: 09/06/2022

LD50 (Rabbit): > 1,500 mg/kg Application Route: Intravenous

LD50 (Dog): > 1,500 mg/kg Application Route: Intravenous

#### Skin corrosion/irritation

Not classified based on available information.

#### Serious eye damage/eye irritation

Not classified based on available information.

## Respiratory or skin sensitization

#### Skin sensitization

Not classified based on available information.

## Respiratory sensitization

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

## **Components:**

#### Cefuroxime:

Result : Sensitizer

## Germ cell mutagenicity

Not classified based on available information.

# **Components:**

## Cefuroxime:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosomal aberration

Result: positive

Test Type: In vitro mammalian cell gene mutation test

Test system: mouse lymphoma cells

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Result: negative

#### Carcinogenicity

Not classified based on available information.

## Reproductive toxicity

Not classified based on available information.

according to the Hazardous Products Regulations



# **Cefuroxime Formulation**

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 2.3 11/30/2023 10844573-00005 Date of first issue: 09/06/2022

#### **Components:**

Cefuroxime:

Effects on fertility : Test Type: Fertility

Species: Mouse

Application Route: Oral

Fertility: NOAEL: 6,400 mg/kg body weight

Symptoms: No adverse effects.

Test Type: Fertility Species: Rabbit Application Route: Oral

Fertility: NOAEL: 400 mg/kg body weight

Symptoms: No adverse effects.

## STOT-single exposure

Not classified based on available information.

#### STOT-repeated exposure

May cause damage to organs through prolonged or repeated exposure.

## **Components:**

# Cefuroxime:

Assessment : May cause damage to organs through prolonged or repeated

exposure.

## Repeated dose toxicity

#### Components:

#### Cefuroxime:

Species : Rat
NOAEL : 900 mg/kg
Application Route : Subcutaneous

Exposure time : 3 M

Symptoms : No adverse effects.

 Species
 : Dog

 NOAEL
 : 400 mg/kg

 LOAEL
 : 1,600 mg/kg

Application Route : Oral Exposure time : 27 W Target Organs : Blood

Symptoms : Gastrointestinal disturbance

Species : Monkey
NOAEL : 450 mg/kg
Application Route : Subcutaneous

Exposure time : 1 M

Target Organs : Blood, Urinary tract

Remarks : May cause damage to organs.

according to the Hazardous Products Regulations



# **Cefuroxime Formulation**

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 2.3 11/30/2023 10844573-00005 Date of first issue: 09/06/2022

#### **Aspiration toxicity**

Not classified based on available information.

## **Experience with human exposure**

## **Components:**

Cefuroxime:

General Information : Repeated contact may cause allergic reactions in very sus-

ceptible persons.

Inhalation : Symptoms: Nausea, Vomiting, Abdominal pain, vaginitis,

Headache, Dizziness, dry mouth, Fatigue, constipation, colitis

# **SECTION 12. ECOLOGICAL INFORMATION**

## **Ecotoxicity**

## **Components:**

#### Cefuroxime:

# **Ecotoxicology Assessment**

Acute aquatic toxicity : Toxic effects cannot be excluded

Chronic aquatic toxicity : Toxic effects cannot be excluded

# Persistence and degradability

No data available

## **Bioaccumulative potential**

## **Components:**

## Cefuroxime:

Partition coefficient: n-

octanol/water

: log Pow: -0.429

# Mobility in soil

No data available

## Other adverse effects

No data available

#### **SECTION 13. DISPOSAL CONSIDERATIONS**

## Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

according to the Hazardous Products Regulations



# **Cefuroxime Formulation**

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 2.3 11/30/2023 10844573-00005 Date of first issue: 09/06/2022

## **SECTION 14. TRANSPORT INFORMATION**

#### International Regulations

#### **UNRTDG**

Not regulated as a dangerous good

#### **IATA-DGR**

Not regulated as a dangerous good

#### **IMDG-Code**

Not regulated as a dangerous good

#### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

## **Domestic regulation**

#### TDG

Not regulated as a dangerous good

## Special precautions for user

Not applicable

# **SECTION 15. REGULATORY INFORMATION**

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

#### **SECTION 16. OTHER INFORMATION**

#### Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median

according to the Hazardous Products Regulations



## **Cefuroxime Formulation**

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 2.3 11/30/2023 10844573-00005 Date of first issue: 09/06/2022

Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety

Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Revision Date : 11/30/2023 Date format : mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8